Johnson Controls International PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Johnson Controls International PLC trades at $141.07 (market cap $85.03B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: Johnson Controls International PLC pays a 1.15% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| JCI | XBI | |
|---|---|---|
Market Cap | $85.03B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $148.21 | $164.28 |
52-Week Low | $103.24 | $85.16 |
Enterprise Value | $93.86B | — |
Dividend Yield | 1.15% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →